Clinical trial
Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With…
NCT00445900 · Mayo Clinic, Other · Completed
Key facts
| NCT number | NCT00445900 |
|---|---|
| Title | Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia |
| Official title | Phase II Study of the Combination of Low-Dose Thalidomide, Prednisone, and Oral Cyclophosphamide ("TPC") in the Therapy of Myelofibrosis With Myeloid Metaplasia (MMM) |
| Lead sponsor | Mayo Clinic, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Myeloproliferative Disorders, Secondary Myelofibrosis |
| Intervention type | Drug, Other, Procedure |
| Interventions | cyclophosphamide, prednisone, thalidomide, immunohistochemistry staining method, laboratory biomarker analysis, biopsy |
| Enrollment | 22 |
| Start date | Oct 1, 2004 |
| Primary completion | Oct 1, 2006 |
| Completion | Oct 1, 2006 |
| First posted | Mar 9, 2007 |
| Last update posted | Mar 17, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: